VDR多态性及其对口腔状细胞癌易感性的影响:系统性审查
Mithra N Hegde1, Nireeksha1, Harshitha Somanatha2
1Department of Conservative Dentistry and Endodontics, A B Shetty Memorial Institute of Dental Sciences, Nitte (Deemed to be University), Mangaluru, India.
Frontiers in oral health
|March 11, 2026
概括
维生素D受体 (VDR) 基因变异,特别是单核酸多态性 (SNP),与口腔状细胞癌 (OSCC) 的风险增加有关. 需要进一步的研究来证实这些VDR基因SNP的临床意义.
科学领域:
- 遗传学和分子生物学
- 在瘤学瘤学.
- 营养科学 营养科学
背景情况:
- 口腔状细胞癌 (OSCC) 的发展涉及遗传和环境因素.
- 维生素D受体 (VDR) 基因变异,包括单核酸多态 (SNP),正在研究它们在OSCC易感性和进展中的潜在作用.
研究的目的:
- 系统地审查和评估VDR基因多态化与OSCC易感性之间的关联.
- 评估相关的人类病例控制研究的方法质量和潜在偏差.
主要方法:
- 在PubMed,Scopus和谷歌学者中进行了系统的文献搜索.
- 在选了90个记录后,包括了五项病例控制研究.
- 纽卡斯尔-太华尺度 (NOS) 用于质量评估;由于研究异质性,不能进行元分析.
主要成果:
- 在VDR基因多态 (Fok1,TaqI,ApaI) 和CYP24A1基因变体和OSCC敏感性之间发现了一致的关联.
- 这些VDRSNP也可能与口腔潜在恶性疾病 (OPMDs) 有关.
- 大多数研究表明偏差风险低,并支持这些SNP在OSCC风险和预后中的作用.
结论:
- VDR多态可能通过免疫和细胞通路影响OSCC风险.
- 虽然有希望,但需要进行更大规模的多民族研究来验证OSCC中VDR基因变异的临床意义.
相关概念视频
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
81
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
81
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
61
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
85
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
85
Principles of Pharmacogenetics: Types of Genetic Variants
69
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
69
Single Nucleotide Polymorphisms-SNPs
19.3K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.3K
Pharmacogenetics of Drug Metabolism: Overview
84
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
84


